This inventor holds 3 USPTO granted patents and 4 published patent applications, plus 1 CIPO patent and 1 EPO patent. Top assignees: Genentech, Inc., Hoffmann-La Roche Inc.. Active years: 2020-2023.
Location History:
- Loerrach, DE (2021)
- Basel, CH (2020 - 2023)
Company Filing History:
3 out of 3,294 
2 out of 5,020 
Years Active: 2020-2023
Title: Christine Wurth: Innovator in Antibody Formulations
Introduction
Christine Wurth is a notable inventor based in Loerrach, Germany. She has made significant contributions to the field of pharmaceutical formulations, particularly in the development of antibody therapies for cancer treatment. With a total of 3 patents to her name, her work has the potential to impact the lives of many patients.
Latest Patents
Wurth's latest patents include innovative formulations for subcutaneous administration of HER2 antibodies. These fixed-dose formulations are designed for the treatment of cancer and include both pertuzumab and co-formulations of pertuzumab and trastuzumab. Additionally, she has developed stable aqueous pharmaceutical formulations that comprise a therapeutic antibody, trehalose, a buffer, and optional surfactant, with a pH range of about 5.5 to about 7.0. These formulations are crucial for enhancing the stability and efficacy of antibody therapies.
Career Highlights
Throughout her career, Christine Wurth has worked with prominent companies in the pharmaceutical industry, including Genentech, Inc. and Hoffmann-La Roche Inc. Her experience in these organizations has allowed her to refine her expertise in antibody formulation and drug development.
Collaborations
Wurth has collaborated with talented professionals in her field, including Jennifer Eng-Wong and Whitney Kirschbrown. These collaborations have contributed to her innovative work and the advancement of antibody therapies.
Conclusion
Christine Wurth is a pioneering inventor whose work in antibody formulations is paving the way for new cancer treatments. Her contributions to the pharmaceutical industry are significant and continue to influence the development of effective therapies.